Tariffs, Cuts Deter Early-Stage Biotech Investment
Cassel Salpeter's third-quarter report links reduced backing for young biotech firms to U.S. government actions.
Updated on Nov. 18, 2026 in Healthcare

Cassel Salpeter's third-quarter healthcare investment report attributes deterred investment in early-stage biotechs to U.S. government actions. The firm tracked 41 biotech and pharma takeovers in the third quarter, up slightly from 40 a year earlier.
Why it matters
Investors are reluctant to back early-stage biotechs amid tariff uncertainty and FDA turmoil, and smaller firms may lack resources to onshore manufacturing or absorb higher lab material costs. The Biotechnology Innovation Organization has proposed a new White House Office of Biotechnology in response to growing competition from China.
Cassel Salpeter tracked 41 biotech and pharma takeovers in the third quarter, up slightly from 40 in the same period of 2025, while overall third-quarter M&A activity trails the prior three quarters. Federal NIH funding has been cut by $18 billion under the One Big Beautiful Bill Act, leaving a 2026 budget of $27.5 billion, and the full impact on early-stage fundraising has not been quantified.
The players
Cassel Salpeter
Cassel Salpeter is a healthcare investment firm that publishes quarterly reports tracking mergers, acquisitions and private placements in the biotech and pharmaceutical sectors.
Trump administration
The Trump administration is the U.S. executive branch led by President Donald Trump, whose policies on tariffs, federal research funding and FDA staffing have shaped the biotech investment climate.
Biotechnology Innovation Organization
The Biotechnology Innovation Organization is a trade group representing biotech companies that has proposed a new White House Office of Biotechnology to address competition from China.
The details
Cassel Salpeter's report says tariff uncertainty is keeping investors on the sidelines for early-stage biotech companies, while slower federal grants and rising operating costs make fundraising difficult. Larger drugmakers have avoided tariffs by committing to U.S. investments and striking deals with the government, but smaller firms may lack the resources to do the same.
Timeline
January 2025: Trump began his second term, and layoffs and disruptions at the FDA followed.
Summer 2025: The One Big Beautiful Bill Act was signed into law, cutting NIH funding by $18 billion.
Q3 2025: Biotech and pharma deals totaled 40 for the quarter.
2026: NIH's budget was reduced to $27.5 billion.
Q3 2026: Cassel Salpeter tracked 41 biotech and pharma takeovers.
Market Landscape
The $18 billion NIH cut under the One Big Beautiful Bill Act is now showing up in early-stage biotech fundraising, a pressure point distinct from the large drugmakers that have struck tariff-avoiding deals with the government. Competition from China is driving industry calls, such as the Biotechnology Innovation Organization's proposal for a White House Office of Biotechnology, to counter the shift.
Reduced early-stage biotech funding can slow the development of new drugs and treatments that eventually reach patients. Consumers and patients may see the effects over time through fewer new therapies entering the market.
The takeaway
Government funding and trade policy now shape which early-stage biotech companies can raise capital, which in turn affects the pipeline of new medicines. Tracking quarterly investment reports can help readers see where that pressure is building.
Further reading
Explore more on Healthcare for the latest on how policy is reshaping drug development and biotech funding.
Source note: This article includes information reported by Pharma.






